NCT05421013View on ClinicalTrials.gov

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions
Facial isSCC
Interventions
DRUG

STP705

STP705 targets TGFB-1 and COX-2 mRNA respectively.

Trial Locations (1)

33180

Center for Clinical and Cosmetic Research, Aventura

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT05421013 - Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC | Biotech Hunter | Biotech Hunter